BPC-157 use rises 33-fold despite limited human evidence

BPC-157 use rose roughly 33-fold from 2020 to 2026 in a September 2026 preprint that reviewed over 15 million clinical records and found 1,039 documented users.

Evidence grade: Early (small, animal, cell or preprint). The finding matters because about 33% of documented users cited pain relief, compared with 4% who cited performance enhancement, while human safety and efficacy data remain limited.

“The study found that BPC-157 use is largely hidden in clinical narrative rather than conventional prescription data,” Venky Soundararajan, co-founder and chief scientific officer of nference and the preprint’s lead author, told Healthline.

The preprint found that 27% of the 1,039 documented users reported improvements. Soundararajan said pain relief appeared in 183 patient records, while wound or tissue healing appeared in 38 and functional return in 34.

“The user population for BPC-157 peptide is increasingly male in proportion and increasingly younger with each passing year,” Soundararajan said. Newly documented male users rose from 57% in 2020 to 70% in 2026, he said.

BPC-157 is a lab-made peptide of 15 amino acids sold online in wellness markets. Healthline reported that promoters describe it as an injectable aid for recovery, pain and tissue repair, and that some advocates pair it with TB-500.

The clinical evidence is much thinner than the marketing claims. Healthline cited a 2025 systematic review that found BPC-157 literature was dominated by preclinical studies and low-grade human evidence, with insufficient clinical safety data. A 2021 retrospective knee-pain study followed 16 people, had no control group and did not measure function or quality of life.

A 2025 intravenous safety pilot involved two participants.

Bert Mandelbaum, a sports medicine specialist and orthopedic surgeon at Cedars-Sinai Orthopaedics and Sports Medicine, told Healthline: “There is zero indication that BPC-157 has any efficacy for pain.” He added: “There’s zero evidence that shows that it’s good for clinical healing, and we don’t really understand the safety profile of it.”

The regulatory picture is unsettled. A Food and Drug Administration advisory committee voted 8-6, with one abstention, at its July 23-24 meeting to add BPC-157 to the Section 503A bulk drug substances list, allowing pharmacies to use it in compounded medicines. Healthline reported that the recommendation did not make BPC-157 an FDA-approved drug, and the agency has not issued final peptide decisions.

Safety questions also remain. Healthline reported that the World Anti-Doping Agency bans BPC-157 as an unapproved substance for athletes in and out of competition. The FDA has said peptides such as BPC-157 free base may be affected by formulation, processing, environmental conditions and impurities, and that it has limited safety information on administration.

The preprint cannot establish a reliable link between BPC-157 and reported improvements or adverse effects, because it was based on routine clinical notes rather than a randomized trial. Its findings apply to people whose use appeared in medical records, not to all people buying or using the peptide.

Experts cited by Healthline urged people considering unapproved peptides to discuss use with a clinician and ask about evidence, quality and alternatives with established safety and effectiveness records.

Source: Healthline News article, Oct. 4, 2026; September 2026 preprint described by Healthline.

Atlas360 reports health research and does not provide medical advice.